CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer

Figure 3

The survival study of CLDN4 expression in individuals diagnosed with OC. (a–c) Survival curves of overall survival, disease-specific survival, and progression-free survival for patients with OC who had high or low levels of CLDN4. The ROC curve was used to confirm that the expression of CLDN4 for (d) OS, (e) DSS, and (f) PFI is effective as a prediction tool.

(a)

(b)

(c)

(d)

(e)

(f)